Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs

<p>Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other potential programs leveraging Abogen's RNA proprietary platform SUZHOU, China, Oct. 2, 2026 /PRNewswire/ -- Abogen Biosciences ("Abogen" or...</p>